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Abstract A randomized, placebo-controlled, efficacy
trial of Carraguard was unable to demonstrate a reduction
in women’s risk of HIV infection, which may have been
due, in part, to low adherence (gel used in 42 % of vaginal
sex acts, on average). A secondary analysis was undertaken
to understand baseline factors associated with high adher-
ence (gel used in C85 % of sex acts). Women who reported
C1 vaginal sex act, returned C1 opened applicator, and had
C1 conclusive post-enrollment HIV test (N = 5990) were
included. Adherence was estimated as the ratio of average
weekly applicator insertions (based on a dye stain assay
indicating vaginal insertion)/average weekly sex acts (by
self-report). Multivariate logistic regression modeling
indicated that coital frequency, site, contraception, and
partner age difference had a significant impact on adher-
ence. Women reporting[1 and B2 vaginal sex acts per
week, on average, were half as likely to be adherent as
those reporting 1 vaginal sex act per week or less [adjusted
odds ratio (AOR): 0.48; 95 % CI 0.38–0.61]; women from
the Western Cape had one-third the odds of being adherent
compared to women from KZN (AOR: 0.31; 95 % CI
0.23–0.41); compared to women using injectable contra-
ception, women using any other or no method were more
likely to be adherent (AOR: 1.30; 95 % CI 1.04–1.63); and
women who had a larger age gap from their partners were
more likely to be adherent (AOR: 1.03; 95 % CI 1.01–1.05;
p = 0.001). Despite low adherence, overall, 13 % of par-
ticipants achieved nearly perfect adherence, indicating a
potential niche for a coitally dependent microbicide. More
research is needed on the impact of sexual patterns and
HIV risk perception on product acceptability and adher-
ence to improve counseling in ongoing trials and when
products are eventually introduced.
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Introduction
Globally, 60 % of new infections among 15–24 year olds
occur in females, and 80 % of young women living with
HIV and AIDS are in sub-Saharan Africa [1]. A host of
biological and socio-cultural factors puts women, and
young women, in particular, at greater risk of HIV acqui-
sition than men [1, 2]. To arm women with an HIV pre-
vention method within their control—or, at a minimum,
that they can initiate—scientists have been developing
vaginal microbicides [2]. Results of most trials conducted
since the late 1990s have been disappointing. Large-scale
trials of Savvy [3, 4], Carraguard [5], Pro-2000 gel [6, 7]
and BufferGel [6] found no effect on HIV incidence. The
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Col-1492 trial of nonoxynol-9 demonstrated increased HIV
risk and a Phase 3 cellulose sulfate (CS) trial was stopped
early due to potential harm [8, 9]. To date, only CAPRISA
004, the first trial of an anti-retroviral (ARV)-based
microbicide, tenofovir gel, has been able to demonstrate a
significant (39 %) reduction in HIV risk in women [10].
More recently, failure to demonstrate effectiveness in
large-scale trials of oral pre-exposure prophylaxis (PrEP)
for women has been attributed to low levels of adherence.
In the FEM-PrEP trial of once daily oral Truvada [teno-
fovir disoproxil fumarate (TDF) and emtricitabine (FTC)],
drug levels indicated that less than 40 % of HIV-uninfected
participants had evidence of recent pill use, leading to early
closure of the trial [11]. Similarly, the Vaginal and Oral
Interventions to Control the Epidemic (VOICE) study was
unable to demonstrate effectiveness of two oral PrEP reg-
imens (TDF-FTC or TDF alone) due to low adherence,
estimated to be around 30 % [12].
Mathematical models have shown that a product’s
effectiveness will be directly affected by the exact amount
of product nonuse; for example, a 40 % efficacious product
used in 50 % of sex acts would yield an effectiveness level
of 20 % [13, 14]. The impact of adherence on effectiveness
is illustrated by the dramatic difference in the outcomes of
FEM-PrEP and VOICE compared to two other oral PrEP
trials, Partners in Prevention [15] and the Botswana Oral
PrEP study [16], both of which demonstrated a significant
effect (62–75 %) in reducing the risk of HIV when
adherence (based on drug levels) was estimated to be about
80 %, on average. The impact of adherence on effective-
ness was also found in CAPRISA 004, in which tenofovir’s
protective effect rose to 54 % among women using gel
during more than 80 % of sex acts [10].
Measuring adherence is complex, time-consuming, and
requires considerable resources, even when biomarkers
(such as drug levels in blood or urine) can be measured.
Because none of the first-generation candidate microbi-
cides was systemically absorbed, measuring adherence was
even more challenging, as no biomarker could be used
[17]. Therefore, participants’ self-reports were the primary
adherence measure in numerous large-scale trials and were
supplemented, in some cases, by counting [7] or weighing
returned applicators [18–20]. The Carraguard Phase 3
efficacy trial was the first study to incorporate a dye stain
assay (DSA) as an objective marker of applicator insertion.
The DSA was developed and validated (97.5 % sensitivity,
96 % specificity) in preparation for the Phase 3 trial [21,
22]. In a review of several subsequent DSA validation
experiments with other applicators and gels, Katzen et al.
concluded that the DSA consistently yielded high (over
90 %) sensitivity and specificity on single-use applicators
used once before sex [23]. The DSA has since been vali-
dated on Microlax applicators stored for up to four months
[23] and used post-coitus [24]. The DSA involves spraying
applicators with a solution made from blue food dye
powder and water that reacts to vaginal mucous. Applica-
tors exhibit a characteristic turquoise streaking pattern if
they have been vaginally inserted (Fig. 1).
Based on the DSA results, gel was estimated to have
been used in only 42 % of sex acts, overall, which may
have contributed to the lack of protective effect found in
the Carraguard Phase 3 trial [5]. In an effort to inform
product development and to provide recommendations for
future microbicide trials, an analysis was undertaken to
identify baseline factors associated with high adherence in
the Carraguard Phase 3 trial. Previous research on predic-
tors of microbicide adherence has been limited, with
varying results. In two small studies, one among women
considered to be at high risk of HIV in the US (N = 96)
who used a commercial lubricant for 2 weeks as a proxy
for a microbicide [25], and another among female sex
workers in Madagascar (N = 192) who used a diaphragm
with or without a microbicide for 4 weeks [26], less ‘‘re-
lationship power’’ (measured by partner resistance or vio-
lence related to suggested condom use) was associated with
higher rates of adherence. By contrast, age (older women)
and privacy (more than one room for sleeping) were
associated with more consistent gel use among women
enrolled with their HIV-positive partners (N = 544) at the
Uganda site of MDP 301, a Phase 3 efficacy trial of Pro-
2000 gel [27]. In a six-month study among monogamous
Zimbabwean women (N = 117) using a microbicide gel
with or without a diaphragm, positive partnership dynamics
(partner approving of product use, consistent condom use)
were predictors of consistent use [28], whereas no associ-
ation was found between psychosocial variables (such as
couple harmony, HIV risk perception) and consistent gel
use among married women (N = 100) from the Pune,
India, site of HPTN 059, a Phase 2 trial of tenofovir gel
[29]. This is the first analysis to be undertaken using the
DSA as an objective adherence marker (versus self-report)
to evaluate baseline predictors of high adherence in a large-
scale microbicide trial.
Methods
Carraguard Phase 3 Trial—Design and Population
The Carraguard trial was a Phase 3, randomized, placebo-
controlled, double-blind trial to assess the efficacy of Car-
raguard, a carrageenan-based gel, in preventing HIV infec-
tion in women (N = 6202) conducted at three South African
sites: Gugulethu [University of Cape Town (UCT)], Wes-
tern Cape (N = 2315), Soshanguve (Medunsa), Gauteng
(N = 2402), and Isipingo [Medical Research Council
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(MRC)], KwaZulu-Natal (N = 1485). Methods and
results have been described in detail previously [5].
Briefly, participants were sexually active (defined as
having had vaginal sex at least once in the 3 months
before screening), HIV-negative, non-pregnant women 16
and older who were randomly assigned (1:1 ratio) to use
Carraguard or a placebo (methylcellulose). Both gels were
packaged identically in single-use Microlax-type appli-
cators (Tectubes Sweden AB, A˚
´
storp, Sweden), each fil-
led with 5 mL to deliver a 4 mL dose. At enrollment,
participants were given two boxes of gel applicators (15
per box) and were instructed to insert one dose of gel up
to 1 h before each vaginal sex act, with no maximum
limit; to insert a new applicator for each act, even if more
than one act occurred within an hour; to insert a new dose
if vaginal sex occurred more than 1 h after gel insertion;
to use the gel only vaginally; and to use condoms with
the gel.
Participants attended the clinic 1 month after enrollment
and quarterly thereafter for a minimum of nine and a
maximum of 24 months of follow-up. Each visit included a
pelvic exam; testing for HIV, pregnancy, and sexually
transmitted infections (STIs); counseling on HIV risk
reduction and adherence; and an interviewer-administered,
structured behavioral questionnaire (BQ). The BQ col-
lected participants’ self-reported data on the number of
vaginal sex acts in the 2 weeks before the visit, if study gel
was used during the last vaginal sex act, if a condom was
used during the last vaginal sex act, and whether unpro-
tected oral or anal sex had occurred since the last study
visit. The BQ also included questions about HIV risk
factors (such as partner abuse, drug use, multiple partners,
sex in exchange for money or goods) and intravaginal
practices.
Participants were instructed not to wash their used
applicators, to store each used applicator in an individual
plastic bag (supplied by the study), and to return all used and
unused applicators at each visit. Women were informed that
applicators might be saved for future research, but were not
told specifically about the DSA because of concerns that
prior knowledge of applicator testing might affect women’s
behavior, although the results would not affect ongoing
participation. Gel resupply was determined individually
during counseling sessions, based on previous gel use
(number of opened applicators returned and participants’
self-reported use since the previous visit) and expected use in
the next 3 months. All applicators that were returned opened
(presumably used) were tested to confirm vaginal insertion
using the DSA, which was introduced after training and
validation at each site. Because of the time lag between study
start (March 2004) and initiation of the DSA (November
2004), some applicators were stored for up to a year before
being tested. Once the backlog of applicators had been tes-
ted, applicators were batch tested with the DSA on an
ongoing basis throughout the remainder of the trial.
Adherence Assessment
The primary adherence measure was ‘‘covered’’ sex acts or
the percentage of vaginal sex acts in which gel was used.
For each participant, the numerator, ‘‘average weekly
insertions,’’ was derived by summing the total number of
Not inserted Inserted
Fig. 1 Dye stain assay for determining applicator insertion
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applicators inserted (per the DSA) and dividing by the
number of weeks in the trial. The denominator, ‘‘average
weekly vaginal sex acts,’’ was calculated by taking the
average of the number of vaginal sex acts reported at each
visit (per the BQ) and dividing by two (reports at each visit
were for the previous 2 weeks). For example, a woman
who participated for 52 weeks and inserted 50 applicators
(per the DSA) would have an average weekly insertion of
0.96 applicators (50 inserted applicators overall/52 weeks
in study). Assuming this participant reported 3, 1, 5, 0, and
4 vaginal sex acts (in the past two weeks) at her Months 1,
3, 6, 9, and 12 follow-up visits, respectively, her average
weekly vaginal sex acts would be 1.3 ([3?1?5?0?4]/5
study visits/2 weeks). Therefore, the participant was
adherent 74 % of the time (0.96 weekly insertions/1.3
vaginal sex acts, per week). For this analysis, participants
were considered ‘‘adherent’’ if they used gel during 85 %
or more of vaginal sex acts, corresponding to the adherence
level required for 80 % power to detect a 33 % efficacious
product [30], the aim of Carraguard Phase 3 trial.
Statistical Analysis
This analysis included the 5990 participants (96.6 % of the
enrolled population) who had at least one conclusive post-
enrollment HIV test, returned at least one opened appli-
cator, and reported at least one vaginal sex act, and
excluded participants who had no DSA results recorded.
Stata (version 12.1; StataCorp LP, College Station, TX)
was used for all analyses. To examine differences in
characteristics between adherent and nonadherent popula-
tions, Pearson chi-square (x2) tests were performed for
categorical variables and t tests were performed for con-
tinuous variables, using the significance level of p\ 0.05.
Continuous variables with a non-linear relationship to the
dependent variable (covered sex acts) were converted to
categorical variables [31]. Logistic regression was used to
estimate the odds ratio (OR) and corresponding 95 %
confidence intervals (CIs) for the relationship between
predictors of interest and adherence. Reference categories
were chosen to be those associated with higher adherence.
Bivariate analysis was used to determine covariates for the
final model based on inclusion criteria of p\ 0.05. Man-
ual, backward, stepwise elimination was used to develop
the final model. Age group and condom use at last sex were
retained in all models, regardless of significance, due to a
priori assumptions that they were likely to be associated
with adherence. Treatment group was included to account
for study design. Income and education were not included
in the final model, because data were only collected at exit
from a random sample of participants (N = 1601) and
inclusion of those variables would have reduced the anal-
ysis sample substantially.
Ethical Approval
The protocol (Population Council No. 322) was reviewed
and approved by the Population Council Institutional
Review Board (NY, USA); the University of KwaZulu-
Natal (KZN) Biomedical Research Ethics Committee for
the Medical Research Council (MRC); the University of
Limpopo, Research, Ethics and Publication Committee for
Medunsa; the University of Cape Town (UCT) Research
Ethics Committee; and the South African Medicines Con-
trol Council (reference no. 20031003); and is registered at
ClinicalTrials.gov (NCT00213083). All participants gave
written informed consent before screening and enrollment
into the trial.
Results
Baseline Characteristics
As shown in Table 1, there were several significant dif-
ferences in baseline characteristics between the adherent
(N = 764) and nonadherent (N = 5226) participants. Most
notably, the average weekly vaginal sex acts at baseline
was 1.3 for adherent women versus 2.1 times per week for
those who were nonadherent (p\ 0.001). There were also
significant differences between sites (p\ 0.001); UCT
had the lowest percentage of adherent women (4.7 %) and
the MRC had the highest (20.3 %). Although there was no
significant difference in average age, overall, between
adherent and nonadherent women (30.9 and 30.3, respec-
tively), there was a significant difference by age group;
women 21–29 were the least adherent group compared to
both younger (16–20 year olds) and older women
(C30 years old).
Summary of Sexual Activity and Adherence During
Follow-up
The mean length of participation, overall, was 1.31 years,
with 30 % of women completing the maximum of 2 years.
The average length of follow-up for adherent women was
1.08 years compared to 1.39 years for nonadherent women
(Cochran-Mantel–Haenszel test of general association,
p\ 0.0001). Table 2 summarizes self-reported data on
sexual activity, gel and condom use from the BQ and DSA
results over the course of the trial. Overall, 90 % of
applicators that had been issued were returned by partici-
pants, with no differences between those who were
adherent or not. In addition, there was no difference by
study group (Carraguard versus placebo) in the percentage
of adherent versus nonadherent participants. According to
DSA results, average weekly applicator insertions (total
2568 AIDS Behav (2016) 20:2565–2577
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Table 1 Characteristics of Carraguard Phase 3 participants at screening by level of adherence (N = 5990)
Characteristic Nonadherent (\ 85 % sex
acts with gel)
N = 5226
Adherent (C 85 % sex
acts with gel)
N = 764
Total
N = 5990
p valuea
Demographics
Average age (median, SD, range) 30.9 (29, 10.4, 16–72) 30.3 (28, 10.9, 16–66) 5990 0.117
Age group (years) 0.005
16–20 921 (84.0) 175 (16.0) 1096
21–29 1771 (88.4) 233 (11.6) 2004
30–38 1267 (87.5) 181 (12.5) 1448
C39 1267 (87.9) 175 (12.1) 1442
Currently married/living as married 1649 (88.4) 216 (11.6) 1865 0.067
Average years of educationb (median, SD, range) 8.5 (9, 2.8, 0–12) 8.4 (9, 3.2, 0–12) 1593 0.828
Average monthly income, ZARb (median, SD, range) 1112 (800, 1059, 0–8000) 1044 (800, 860, 0–4500) 1594 0.418
Site \0.001
UCT 2129 (95.3) 106 (4.7) 2235
Medunsa 1942 (84.3) 363 (15.8) 2305
MRC 1155 (79.7) 295 (20.3) 1450
Reproductive health
Average weekly vaginal sex acts (median, SD, range) 2.1 (1.5, 2.2, 0–21) 1.3 (1.0, 1.4, 0–13.5) 5990 \0.001
Ever pregnant 4290 (87.5) 614 (12.5) 4904 0.248
Contraceptive method (use of more than one method possible)
Permanent method (sterilization or hysterectomy) 657 (88.0) 89 (11.9) 746 0.471
Injectable (DMPA or Net-EN) 2352 (90.4) 250 (9.6) 2602 \0.001
Oral contraception 403 (86.1) 65 (13.9) 468 \0.001
Male condom 886 (83.0) 181 (17.0) 1067 \0.001
Otherc 97 (91.5) 9 (8.5) 106 0.184
None 1169 (83.4) 232 (16.6) 1401 \0.001
Regular menses 2990 (86.5) 464 (13.4) 3454/5989 0.015
Partnership characteristics
Had more than 1 partner in past 3 months 440 (85.4) 75 (14.6) 515 0.198
Has a steady sexual partner 5167 (87.3) 750 (12.7) 5917 0.098
Age difference with steady partner (median, SD, range) 4.68 (4, 4.84, -22 to 39) 5.07 (4, 5.12, -20 to 36) 5915 0.041
Has other partner(s) 453 (83.3) 91 (16.7) 544 0.004
Steady partner has other partner(s) 0.001
Yes 893 (85.8) 152 (14.6) 1045/5917
No 1761 (89.6) 204 (10.4) 1965/5917
Don’t know 2513 (86.5) 394 (13.6) 2907/5917
Abused by any partner, B3 months 1812 (86.7) 277 (13.3) 2089 0.391
Ever forced sex 550 (86.5) 86 (13.5) 636 0.539
Other HIV risk factors
Condom at last sex, any partner 2654 (88.0) 361 (12.0) 3015 0.068
Condom at last sex, steady partner 1772 (87.6) 250 (12.4) 2022/5916 0.518
Condom at last sex, other partner 284 (83.5) 56 (16.5) 340/544 0.034
Unprotected oral sex, B3 months 436 (88.1) 59 (11.9) 495 0.561
Unprotected anal sex, B3 months 105 (81.4) 24 (18.6) 129 0.044
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number of used applicators divided by the total number of
weeks in the trial) ranged by participant from 0 to 9.5, with
an average of 1.56 insertions among adherent women
versus 0.79 insertions for nonadherent women (p\ 0.001).
The difference in average weekly vaginal sex acts between
those who were adherent or nonadherent continued to be
significant during follow-up; adherent women had a med-
ian of 1.2 acts per week compared to 2.4 acts per week
among nonadherent women (p\ 0.001). The percentage of
‘‘covered’’ sex acts (vaginal sex acts with gel) per partic-
ipant ranged from 0 to 100 %, with an average of 42 %,
overall. Adherent women used gel in 97 % of acts, on
average (range 85–100 %), compared to only 34 %, on
average (range 0–84.5 %) among nonadherent women
(p\ 0.001). Figure 2 further illustrates the distribution of
‘‘covered’’ sex acts, indicating that the majority of partic-
ipants used the gel in no more than 50 % of their vaginal
sex acts. Despite the range of adherence levels indicated by
the DSA (Fig. 2), there were no differences between
adherent (86.9 %) and nonadherent (85.3 %) women in the
proportion reporting at all visits that they had used the gel
during the last vaginal sex act.
In the adherent group, no difference in HIV incidence
was found between those using Carraguard versus placebo;
20 in each group became infected with HIV (Risk
Ratio * 1; p-value * 1.0). In addition, even among
women estimated to have used the gel in 100 % of vaginal
sex acts, 5 % of women in the Carraguard group (16
infections/331 women) and 5 % in the placebo group (15
infections/306 women) seroconverted (log-rank test,
p = 0.80).
Baseline Predictors of Adherence
In bivariate analysis (Table 3), age group, site, coital fre-
quency (average weekly vaginal sex acts), site, contra-
ceptive method, age difference with steady partner, having
other partners, steady partner having multiple partners, and
unprotected anal sex were associated with adherence.
Women who had vaginal sex more than once but less than
twice per week, on average, were less than half as likely to
be adherent compared to women having vaginal sex once
per week or less (OR: 0.46; 95 % CI 0.38–0.56), and the
likelihood of being adherent declined as the average
number of vaginal sex acts per week increased. Compared
to participants from the MRC (KZN) site, participants from
UCT (Western Cape) and Medunsa (Gauteng) had one-fifth
and three-quarters the odds of being adherent, respectively.
Participants who were not using any contraception at
baseline were 1.5 times more likely to be adherent com-
pared to those using contraception. Of those using contra-
ception, women using methods other than injectables were
more likely to be adherent than women using injectables
(OR: 1.55; 95 % CI 1.29–1.86) and women who were not
using condoms for family planning were less likely to be
adherent than those using condoms (OR: 0.54; 95 % CI
0.45–0.66). Women were more likely to be adherent if they
had multiple partners (OR: 1.42; 95 % CI 1.12–1.81) or if
their partners had other partners (OR: 1.38; 95 % CI
1.17–1.64). Compared to women 39 years of age and older,
women in the 16–20 year-old age group were significantly
more likely to be adherent (OR: 1.38; 95 % CI 1.10–1.72),
whereas there were no differences between the other age
groups. Women who reported having had unprotected anal
sex in the 3 months before screening were more likely to
be adherent (OR: 1.58; 95 % CI 1.00–2.48), as were
women with a greater age difference from their partners
(OR: 1.02; 95 % CI 1.00–1.03).
In themultivariatemodel (Table 4), coital frequency, site,
injectable contraception, and age difference from steady
partner remained significant predictors of adherence.
Women having more than one and up to two vaginal sex acts
per week, on average, had less than half the odds of being
adherent as those having one or fewer vaginal sex acts per
week [adjusted odds ratio (AOR): 0.48; 95 %CI 0.38–0.61];
those having more than two and up to three vaginal sex acts
Table 1 continued
Characteristic Nonadherent (\ 85 % sex
acts with gel)
N = 5226
Adherent (C 85 % sex
acts with gel)
N = 764
Total
N = 5990
p valuea
Ever had sex for money 147 (89.6) 17 (10.4) 164 0.352
STI (non-HIV) detected at screening 1358 (87.9) 187 (12.1) 1545 0.373
Unless otherwise indicated, number (%) of participants is noted
ZAR South African Rand
a p values represent v2 test for categorical variables and t test for continuous variables
b Data collected at exit from a random sub-sample of participants only (N = 1601)
c Includes female condom; IUD; diaphragm; traditional methods; other birth control. Types of contraceptives are recorded independently;
therefore, counts may not add up to total N
d Includes physical, emotional, psychological and economic abuse
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per week had approximately one-quarter the odds of being
adherent (AOR: 0.24; 95 % CI 0.16–0.35); and those having
more than three vaginal sex acts per week had less than one-
tenth the odds of being adherent (AOR: 0.06; 95 % CI
0.03–0.11). Participants from UCT (Western Cape) remained
significantly less likely to be adherent (AOR: 0.31; 95 % CI
0.23–0.41) compared towomen from theMRC, although there
wasno longer a significant differencebetween women from the
MRC and Medunsa sites (AOR: 0.98; 95 % CI 0.78–1.23).
Women who had a greater age difference (in years) from their
Table 2 Summary of sexual activity, gel and condom use during the Carraguard Phase 3 trial, by adherence level (N = 5990)
Characteristic Nonadherent (\85 % sex
acts with gel)
N = 5226
Adherent (C85 % sex
acts with gel)
N = 764
Total
N = 5990
p
valuea
Study group 0.983
Carraguard 2622 (87.3) 383 (12.7) 3005
Placebo 2604 (87.2) 381 (12.8) 2985
Average weekly coital frequency
(median, SD, range)
2.7 (2.4, 1.6, 0–18.8) 1.3 (1.2, 0.6, 0–4.7) 2.5 (2.2, 1.6, 0–18.8) \0.001
Percentage returned applicators
(median, SD, range)
89.5 (97.5, 16.1, 1.7–100) 88.4 (97.8,18.5, 8.9–100) 89.4 (97.6, 16.4, 1.7–100) 0.085
Average weekly insertions per DSA
(median, SD, range)
0.79 (0.71, 0.66, 0-4.1) 1.56 (1.45, 0.64, 0–9.5) 0.89 (0.79, 0.6, 0-9.5) \0.001
Percentage vaginal sex acts with gel:
inserted applicators [DSA]/sex acts [self-
report] (median, SD, range)
33.8 (31, 21.8, 0–84.5) 97.3 (100, 4.7, 85–100) 41.9 (35.9, 29.4, 0–100) \0.001
Self-reported gel at last sex 0.115
Always 4458 (87.0) 664 (13.0) 5122/5974
Never 25 (78.1) 7 (21.9) 32/5974
Inconsistent 728 (88.8) 92 (11.2) 820/5974
Self-reported condom at last sex 0.004
Always 1599 (89.3) 192 (10.7) 1791
Never 722 (85.0) 127 (15.0) 849
Inconsistent 2905 (86.7) 445 (13.3) 3350
Unless otherwise indicated, number (%) of participants is noted
a p values represent v2 test for categorical variables and t test for continuous variables
Fig. 2 Distribution of average
adherence (‘‘covered sex acts’’)
by participant, Carraguard
Phase 3 trial (N = 5990)
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steady partners (AOR: 1.03; 95 % CI 1.01–1.05; p = 0.001)
and those who were not using injectable contraception also
had higher odds of being adherent (AOR: 1.30; 95 % CI
1.04–1.63). Age group was no longer a significant predictor
of adherence.
Discussion
In this secondary analysis of data from the Carraguard
Phase 3 trial, despite overall low rates of adherence (per the
DSA), nearly 13 % of participants (764 women) achieved
Table 3 Bivariate logistic regression: baseline predictors of adherence (gel use in C 85 % of sex acts) in the Carraguard Phase 3 trial
(N = 5990)
Variable Unadjusted odds ratio
(95 % confidence interval)
Wald v2 p value
Background characteristics
Age group in years (vs. C39 years)
16–20 1.38 (1.10–1.72) 0.006
21–29 0.92 (0.75–1.13) 0.648
30–38 1.03 (0.82–1.29) 0.766
Not marrieda (vs. legally married/living as married) 1.17 (0.99–1.38) 0.068
Site (MRC reference)
UCT 0.19 (0.15–0.25) \0.001
Medunsa 0.73 (0.62–0.87) \0.001
Carraguard (vs. placebo) 0.99 (0.86–1.16) 0.983
Reproductive health
Coital frequency, last 2 weeks (vs. B1sex act per week)
[1, B2 acts per week 0.46 (0.38–0.56) \0.001
[2, B3 acts per week 0.21 (0.15–0.30) \0.001
[3 acts per week 0.06 (0.03–0.10) \0.001
Irregular menses (vs. regular) 0.86 (0.74–1.00) 0.066
Never pregnant (vs. ever) 1.12 (0.92–1.36) 0.248
Contraceptionb
No sterilization/hysterectomy (vs. yes using) 1.09 (0.86–1.38) 0.471
No injectable (vs. yes using) 1.55 (1.29–1.86) \0.001
No oral contraceptive (vs. yes using) 0.79 (0.60–1.05) 0.099
No condom (vs. yes using) 0.54 (0.45–0.66) \0.001
Not using other (vs. yes using other forms) 1.59 (0.80–3.15) 0.188
None (vs. any contraception) 1.51 (1.28–1.79) \0.001
Partnership characteristics
No steady partner (vs. yes steady partner) 1.63 (0.91–2.94) 0.101
Steady partner age difference (years) 1.02 (1.00–1.03) 0.041
Steady partner has other partners (or doesn’t know)
(vs. partner has no other partners)
1.38 (1.17–1.64) \0.001
Participant has other partners (vs. no other partners) 1.42 (1.12–1.81) 0.004
HIV risk factors
Did not use condom at last sex (vs. used) 0.90 (0.77–1.04) 0.155
Unprotected anal sexc (vs. no unprotected anal sex) 1.58 (1.00–2.48) 0.046
Unprotected oral sexc (vs. no unprotected oral sex) 0.92 (0.69–1.22) 0.561
Ever forced to have sex (vs. never) 1.08 (0.85–1.37) 0.540
Abusec (vs. no abuse) 1.07 (0.91–1.26) 0.391
Ever had sex in exchange for money (vs. never) 0.79 (0.47–1.31) 0.354
STI at screening (vs. no STI at screening) 0.92 (0.77–1.10) 0.373
a Not married = single/never married, divorced, separated, or widowed
b More than one method possible
c In the 3 months prior to screening
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high adherence, having used gel in 85 % or more vaginal
sex acts (N = 383, Carraguard; N = 381, placebo). How-
ever, even among this highly adherent group, there was no
difference in HIV incidence between the Carraguard and
placebo groups, consistent with the lack of protective effect
found in the primary Carraguard Phase 3 trial analysis [5].
Regardless of Carraguard’s lack of effect, a better under-
standing of factors associated with high adherence in this
trial may help to inform future clinical trials and the
development of HIV prevention strategies for women, in
general.
Coital frequency at baseline was one of the most sig-
nificant factors associated with high adherence. The inverse
relationship between coital frequency and adherence was
also found by Turner et al., albeit among a cohort of female
sex workers [26]. Participants (in both studies) were
instructed to insert gel up to an hour before each vaginal
sex act, and to insert a new dose for each act, even if
multiple vaginal sex acts occurred within 1 hour. It is
possible that women may not have been willing or felt the
need to insert new applicators for each vaginal sex act.
Results from a qualitative acceptability sub-study among
Carraguard participants (N = 66) indicate the plausibility
of this theory; of the women who participated in in-depth
interviews, half of those reporting multiple ‘‘rounds’’ of
vaginal sex inserted a new gel applicator for each vaginal
sex act (N = 26/53) whereas the other half (N = 27/53)
did not, either because they did not want to or because they
thought the previously inserted gel would still be effective
[32].
It is also possible that underlying patterns of sexual
encounters rather than coital frequency, overall, led to the
association between coital frequency and adherence. For
example, if Participant X lives with her steady partner and
regularly has vaginal sex once a week, she would report
that she had two vaginal sex acts in the 2 weeks before her
follow-up visit. If Participant Y, who does not live with her
partner, spent the weekend before her study visit with him
and had sex four times, she would have reported four
vaginal sex acts in the previous 2 weeks. Therefore, even
though both women had a total of four vaginal sex acts in
the month preceding their study visits, based on the way
data were collected (number of vaginal sex acts in the
previous 2 weeks), coital frequency is estimated to be one
vaginal sex act per week for Participant X versus two
vaginal sex acts per week for Participant Y. Data from the
qualitative Carraguard sub-study provide further evidence
of the link between sexual patterns and adherence. In
particular, many women reported that they forgot to bring
their gels with them when they went to visit their
Table 4 Multivariate logistic regression model: baseline predictors of adherence (gel use in C85 % of sex acts) in the Carraguard Phase 3 trial
(N = 5990)
Variable Adjusted odds ratio (95 %
confidence interval)
Wald v2 p value
Age group (vs. C39)
16–20 1.16 (0.84–1.61) 0.368
21–29 0.88 (0.66–1.18) 0.406
30–38 1.08 (0.80–1.45) 0.616
Carraguard (vs. placebo) 0.94 (0.77–1.13) 0.49
Site (vs. MRC)
UCT 0.31 (0.23–0.41) \0.001
Medunsa 0.98 (0.78–1.23) 0.862
Average weekly vaginal sex acts (vs. B1 act per week)
[1 and B2 acts per week 0.48 (0.38–0.61) \0.001
[2 and B3 acts per week 0.24 (0.16–0.35) \0.001
[3 acts per week 0.06 (0.03–0.11) \0.001
Age difference with partner (years) 1.03 (1.01–1.05) 0.001
Not using injectable contraception (vs yes using) 1.30 (1.04–1.63) 0.021
Not using condoms for contraception (vs yes using) 0.84 (0.65–1.09) 0.188
Steady partner has other partners or does not know
(vs partner does not have other partners)
1.10 (0.88–1.36) 0.404
Participant has other partners (vs no other partners) 1.20 (0.86–1.66) 0.280
Did not use a condom at last sex, any partner
(vs. used a condom at last sex)
0.90 (0.73–1.12) 0.348
Unprotected anal sex, past 3 months (vs. no unprotected anal sex) 1.32 (0.73–2.39) 0.362
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boyfriends who were living elsewhere, while other women
adjusted their behaviors to keep one box of gel at their
boyfriend/partner’s house and another at home [32]. The
impact of sexual patterns and logistics was also found to be
associated with adherence issues in the recently completed
FACTS 001 trial, in which most participants lived with
their parents and sexual encounters often occurred outside
of their homes [33].
The second factor that was consistently found to have a
significant association with adherence was study site.
Women from the UCT (Western Cape) site had one-third
the odds of being adherent compared to those from
Medunsa (Gauteng, near Pretoria) and the MRC (KZN),
which may have been because they accurately perceived
themselves to be at lower risk of HIV than women at the
other two sites. Risk perception is a key element in
behavioral change theories, such as the health belief model
[34] and the AIDS risk reduction model [35]. Although
HIV risk perception was not measured in the Carraguard
Phase 3 trial, it is possible that women’s individual risk
perception reflected country-wide surveillance data indi-
cating that the Western Cape is the South African province
with the lowest HIV prevalence [36]. Indeed, in compar-
ison to the other sites, UCT had the lowest baseline
prevalence [18 vs. 25 % in Medunsa (Gauteng) and 43 %
at the MRC (KZN)] and incidence (2.7 infections per 100
woman-years versus 3.0 at Medunsa and 6.0 at the MRC)
during the trial [5].
The significant difference in odds of adherence at UCT
compared to the MRC and Medunsa sites may also have
been due to logistical reasons. First, among a subset of
women responding to quantitative, interviewer-adminis-
tered exit interviews (N = 1601), significantly more
women at UCT than the other two sites reported that the
main reason for product nonuse was running out of study
gel [37]. Second, mean length of participation was longer
at UCT than at Medunsa or the MRC (1.35 years versus
1.29 and 1.26 years, respectively; Breslow-Day test,
p = 0.03) [38] and adherence was negatively correlated
with length of study participation. Shorter trials (1 year or
less) and more frequent visits (monthly versus quarterly)
may yield better adherence by minimizing study fatigue
and the impact of resupply.
Contraceptive method was also found to be associated
with adherence. Although injectable contraception was the
most commonly used method, overall, women using any
other method or no method at baseline had higher odds of
adherence. Women using oral contraceptives (OCs) or
condoms for family planning who were already accus-
tomed to behaviors requiring daily or coitally related
adherence may have been more comfortable incorporating
a coitally dependent gel into their routines than women
using injectables. These results are similar to findings from
the Methods for Improving Reproductive Health (MIRA)
trial, which evaluated the diaphragm for HIV prevention.
In the MIRA trial, women reporting condom use at baseline
were more likely to be adherent and women using inject-
able contraception, less likely [39]. On the other hand, in
the FEM-PrEP trial of daily oral Truvada (or placebo),
women using OCs at baseline were less likely to be good
adherers, possibly because they may not have been willing
to take a second pill every day [40].
In this analysis, partner age difference also had a sig-
nificant association with adherence; the greater the age
difference between a woman and her partner, the lower her
odds of being adherent. Having an older partner ([5 years
older) has previously been associated with increasing
young women’s risk of HIV acquisition [36, 41], indicating
that women at higher risk of HIV in the Carraguard trial, by
virtue of having older partners, were less likely to be
adherent than those at lower risk. These results align with
van der Straten et al., who found that women in Zimbabwe
at high HIV risk were less likely to be adherent to use of a
diaphragm with a candidate microbicide [28], but differ
from Mosack et al., who found that less ‘‘relationship
power,’’ which was systematically assessed, was associated
with greater adherence, albeit among a cohort of ‘‘high-
risk’’ women in the United States [25]. Finally, in the
FEM-PrEP trial, the first study of oral PrEP or vaginal
microbicides to systematically assess the impact of risk
perception on adherence, a significant positive association
was found between having some perceived HIV risk at
enrollment and good adherence [42].
The results of this analysis differ from the findings of
Abaasa et al. [27], who found that older age and living in a
household with more rooms for sleeping were associated
with more consistent gel use at the Uganda MDP 301 trial
site. The differences between the sites (rural Uganda in
MDP 301 versus peri-urban South Africa in the Carraguard
trial) and cohorts (discordant couples in Uganda versus
sexually active women from the general population in
South Africa), which tested similar broad-spectrum gels,
both to be used within 1 hour of each sex act, highlights the
importance of understanding the influence of contextual
issues on adherence [17, 43].
Limitations
There were several limitations to this analysis, and to the
DSA, in particular. First, despite being a highly sensitive
and specific measure of applicator insertion, the DSA
cannot indicate if an applicator was inserted in conjunction
with a specific vaginal sex act, nor whether gel was actu-
ally expelled into the vagina [44, 45]. Although training
was conducted at each site prior to introducing the DSA, it
is possible that readers became fatigued over time and,
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therefore, results could have been variable over the course
of the trial. Additionally, because the assay was validated
after the Phase 3 trial started, many applicators were stored
for up to 1 year before being tested, which also could have
affected the accuracy of the test. Finally, because appli-
cator testing was not performed in connection to specific
study visits, it was not possible to measure adherence by
visit for each participant, but only to estimate adherence
based average weekly insertions over the course of the
entire trial. The lack of per-visit adherence measures also
precluded an analysis of patterns of adherence over time.
Second, the measure of adherence is potentially flawed
if self-reports of coital frequency were inaccurate. Women
reported the number of sex acts in the 2 weeks prior to
each quarterly visit, which was then extrapolated to the
entire three-month period. If the denominator (number of
sex acts) in the calculation of adherence was incorrect, it
would have an impact on the overall ratio. Under reports of
sexual activity would result in adherence being overesti-
mated, while over reports of sexual activity would result in
adherence being underestimated. If under and over
reporting occurred with equal frequency, however, the
outcome would be a higher estimate of adherence than
actually occurred.
Results from a placebo gel trial at the same South
African sites, however, in which self-reports and applicator
testing both occurred monthly, indicated a similar per-
centage of sex acts with gel (44 % overall, over 3 months),
with declining adherence over time [46]. Hence, it is
conceivable that the overall level of adherence measured in
this study (gel use in 42 % of sex acts) is accurate.
Finally, women who were not willing to abstain from
intravaginal practices at screening were excluded from the
trial. Once enrolled, women were asked quarterly about
vaginal practices in conjunction with gel use (and were not
discontinued from the trial); however, data on these prac-
tices were not collected at baseline. Therefore, it was not
possible to assess the association between vaginal practices
and adherence.
Conclusion
The results of this analysis are important for the future of
microbicide development. Given the overall low adherence
to gel use in the Carraguard Phase 3 trial, alternative for-
mulations, such as long-acting intravaginal rings or
injectables may be more feasible for many women at high
risk of HIV. The results of this analysis, however, in which
over 700 women were able to achieve near perfect adher-
ence, indicates that a coitally dependent gel is feasible
for some women who may still be at high risk of HIV.
The relationships between baseline coital frequency,
contraceptive method and adherence in this large efficacy
trial highlight the importance of integrating HIV prevention
strategies into existing family planning programs and may
inform the development of multi-purpose prevention tech-
nologies, designed to prevent pregnancy and HIV simulta-
neously. As illustrated by the between-site differences in this
trial and results from other large-scale trials, no single pro-
duct or formulation will work for all women. Therefore, it is
important to continue developing multiple strategies that
will be feasible for women at various stages of their lives.
This analysis can also help to inform future trials of
microbicides and other HIV prevention strategies. Objec-
tive markers of adherence, such as the DSA, are extremely
valuable for measuring adherence throughout a clinical
trial, even when biomarkers are feasible. The ongoing use
of biomarkers is prohibitively expensive; could potentially
lead to a ‘‘white coat’’ effect, when participants use a
product more regularly prior to a clinic visit; and cannot
measure adherence in the control arm of placebo-controlled
trials. However, even objective markers of adherence
cannot fully explain the complexities of sexual patterns that
may affect adherence. Future trials should consider
including qualitative, in-depth assessments of women’s
sexual patterns and HIV risk perceptions at baseline and
throughout a trial to better predict potential adherence risks
and to better counsel women who may have adherence
challenges during a trial.
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